# Validation Report: CQ13 High-Commercialization Trials

**Status**: [x] Verified
**Date**: 2026-01-12
**Executor**: Antigravity (Virtual Biologist)

## 1. Executive Summary
The validation of CQ13 (High-Commercialization Trials) confirmed the system's ability to act as a **Clinical Intelligence Agent**.
-   **Discovery**: Successfully identified active Phase 3 trials for **Retatrutide** (Obesity/T2D) and **Sacituzumab Govitecan** (Endometrial Cancer).
-   **Commercial Validation**: Web search verified the "hype" surrounding these assets (Retatrutide forecast >$30B; Sacituzumab addressing $39B market).
-   **Workflow Validation**: Confirmed the architecture: ClinicalTrials -> ChEMBL (Mechanism) -> Web (Commercial Context).

## 2. Execution Log

### Phase 1: Trial Discovery (ClinicalTrials.gov)
-   **Query**: "Retatrutide" (Phase 3, Recruiting)
    -   **Result**: `NCT:07232719` (Obesity/Overweight), `NCT:07035093`.
-   **Query**: "Sacituzumab Govitecan" (Phase 3, Recruiting)
    -   **Result**: `NCT:06486441` (Endometrial Cancer), `NCT:06081244` (Breast Cancer).

### Phase 2: Mechanism & Asset Resolution (ChEMBL)
-   **Retatrutide**: Resolved to `CHEMBL:5095485`.
    -   **Mechanism**: Triple agonist (GLP-1/GIP/GCGR) - Validated as "next-gen Mounjaro".
-   **Sacituzumab Govitecan**: Resolved to `CHEMBL:3545262`.
    -   **Mechanism**: TROP-2 Antibody-Drug Conjugate (ADC) - Validated as "Trodelvy".

### Phase 3: Commercial Intelligence (Web Search)
-   **Retatrutide**: "Projected revenue $30B by 2031", "Peak sales $101B" (Clarivate/BioSpace).
-   **Sacituzumab in Endometrial**: "Addressable market $39B by 2030", "Key trial ASCENT-GYN-01".

## 3. Architectural Fit
This CQ validates the **"Temporal" Pattern** described in `architectural-patterns.md`:
-   **Monitoring**: A static query is insufficient. The value is in *monitoring* these trials for status changes (e.g., "Recruiting" -> "Completed").
-   **Alerting**: The system should alert the user when "Retatrutide" Phase 3 results are published.

## 4. Conclusion
CQ13 is a successful test of **Semantic Linkage** between Clinical Data (NCT IDs) and Commercial Intelligence (Web Forecasts).
